NCT06304883 is a long-term extension Phase 3 trial evaluating ALZ-801 (valiltramiprosate), an oral amyloid aggregation inhibitor, in subjects with early Alzheimer's disease who are homozygous for the APOE4 allele (APOE4/4 genotype). This extension study builds upon the earlier APOLLOE4 Phase 3 trial to assess long-term efficacy, safety, and biomarker effects[@hey2020][@vergelli2021].
ALZ-801 represents a first-in-class oral small molecule approach that differs from monoclonal antibody therapies by directly targeting toxic amyloid-beta oligomers rather than clearing existing plaques. This mechanism may offer advantages including no ARIA (amyloid-related imaging abnormalities) risk and easier chronic dosing[@parthasarathy2022].
Trial Details
| Parameter | Value | |-----------|-------| | NCT Number | NCT06304883 | | Phase | Phase 3 | | Status | Active, not recruiting | | Sponsor | Alzheon Inc. | | Enrollment | 163 patients | | Study Type | Interventional | | Start Date | April 2, 2024 | | Expected Completion | January 2027 | | Duration | Up to 2.5 years | | Location | United States (Arizona, California) |
Mechanism of Action
ALZ-801 (valiltramiprosate) is an oral small molecule that targets amyloid-beta oligomerization through a unique mechanism:
Mechanism: Allosteric modulation of Aβ aggregation kinetics
Action: Stabilizes non-toxic Aβ conformations, prevents formation of toxic oligomers
...
Overview
NCT06304883 is a long-term extension Phase 3 trial evaluating ALZ-801 (valiltramiprosate), an oral amyloid aggregation inhibitor, in subjects with early Alzheimer's disease who are homozygous for the APOE4 allele (APOE4/4 genotype). This extension study builds upon the earlier APOLLOE4 Phase 3 trial to assess long-term efficacy, safety, and biomarker effects[@hey2020][@vergelli2021].
ALZ-801 represents a first-in-class oral small molecule approach that differs from monoclonal antibody therapies by directly targeting toxic amyloid-beta oligomers rather than clearing existing plaques. This mechanism may offer advantages including no ARIA (amyloid-related imaging abnormalities) risk and easier chronic dosing[@parthasarathy2022].
Trial Details
| Parameter | Value | |-----------|-------| | NCT Number | NCT06304883 | | Phase | Phase 3 | | Status | Active, not recruiting | | Sponsor | Alzheon Inc. | | Enrollment | 163 patients | | Study Type | Interventional | | Start Date | April 2, 2024 | | Expected Completion | January 2027 | | Duration | Up to 2.5 years | | Location | United States (Arizona, California) |
Mechanism of Action
ALZ-801 (valiltramiprosate) is an oral small molecule that targets amyloid-beta oligomerization through a unique mechanism:
Safety: Incidence, nature, and severity of treatment-emergent adverse events (TEAEs)
Biomarker Assessments
Key biomarker measures include:
CSF amyloid-beta 42 levels
Plasma p-tau217
Amyloid PET (centiloids)
Neurofilament light chain (NfL)
Hippocampal volume (MRI)
Clinical Evidence to Date
Phase 2 Trial Results
The Phase 2 trial demonstrated[@vergelli2021][@abushakra2021]:
Efficacy:
Statistically significant cognitive benefit in APOE4 carriers
Reduced CSF amyloid-beta 42 (indicator of reduced oligomer formation)
Stabilization of hippocampal volume
Reduced tau pathology markers
Safety:
Favorable safety and tolerability profile
No ARIA observed
Low discontinuation rate
Publication
A 2024 publication in the Journal of Prevention of Alzheimer's Disease comprehensive results provided further evidence for ALZ-801's mechanism and clinical effects[@alzheon2024].
Competitive Position
ALZ-801 differs from approved anti-amyloid antibodies: